poisar

Stocks · News reference

Estrella Immunopharma Doses First Participant In Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Jul 24, 2026, 12:02 PMBenzinga Newsdesk

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ESLA
Source
benzinga
Observed
Jul 24, 2026, 12:02 PM
Checked
Jul 24, 2026, 12:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading